搜尋結果
6 天前 · References: World Health Organization. Respiratory Syncytial Virus (RSV) disease. Available at: www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/respiratory-syncytial-virus-disease. Accessed .
2024年2月2日 · Grip strength is globally regarded as a reliable indicator of overall health with its connection to muscle strength, immune health, chronic disease risk and longevity. In addition, it functions as a biomarker of aging as research indicates that individuals with weaker grip strength exhibit signs of accelerated DNA aging.[2]
1 天前 · CONTACT: Scott Way, Executive Vice President, General Counsel. Impulse Dynamics. 856-434-7906. sway@impulsedynamics.com. Rohan More, Global Vice President, Marketing. Impulse Dynamics. 856-642-9933. rmore@impulsedynamics.com. Milestone Highlights Transformative Symptom Management for Patients Living with Heart Failure David and Raynita Marlton ...
2024年4月16日 · The Health Coalition held press conferences to release the report with patients who have been charged hundreds or even thousands of dollars for access to care in for-profit clinics. Most of the patients are seniors on fixed incomes who were charged up to $8,000 or more for eye surgeries and tests, reported the Health Coalition.
2024年4月19日 · FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer. 04月19日 05:00 GlobeNewswire. Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non ...
2024年4月19日 · Kansas City, MO, April 19, 2024 (GLOBE NEWSWIRE) — Today, the American Association of Colleges of Osteopathic Medicine (AACOM) convened a special Friday Forum during it’s Educating Leaders 2024 conference to focus on the emerging concept of “Food as Medicine”. “We are witnessing a dynamic shift in the healthcare landscape.
2024年4月29日 · LOUISVILLE, Ky., April 29, 2024 (GLOBE NEWSWIRE) — Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Day One Biopharmaceuticals for OJEMDA (tovorafenib), which is now FDA approved for the treatment of patients six months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or ...
